Caricamento...
Impact of PSA threshold and screening interval in prostate cancer screening outcomes – Comparing the Swedish and Finnish ERSPC centres
BACKGROUND: The European Randomised Study of Screening for Prostate Cancer trial has shown a 21% reduction in prostate cancer (PC) mortality with prostate-specific antigen (PSA)-based screening. Sweden used a two-year screening interval and showed a larger mortality reduction than Finland with a fou...
Salvato in:
| Pubblicato in: | Eur Urol Focus |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5809235/ https://ncbi.nlm.nih.gov/pubmed/28803925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euf.2017.07.007 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|